Your new post is loading...
From
www
The interaction between menin and oncogenic mixed lineage leukemia (MLL) fusion proteins is required for leukemic transformation and may represent a therapeutic opportunity. In this issue of Cancer Cell, Borkin and colleagues describe the development of highly potent small-molecule inhibitors of this interaction that reverse the leukemic phenotype and prolong survival in murine models of MLL-rearranged leukemia.
Via Krishan Maggon
Cancer cell Volume 27, Issue 4, p431–433, 13 April 2015
Designed to Kill: Novel Menin-MLL Inhibitors Target MLL-Rearranged LeukemiaMichael W.M. Kühn, Scott A. Armstrong DOI: http://dx.doi.org/10.1016/j.ccell.2015.03.012 | Article Info